New immune cell therapy takes on tough lung cancer
NCT ID NCT07246304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called TC-D101 CAR-T for people with a specific type of advanced small cell lung cancer that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer cells, and is given after a short course of chemotherapy. The main goals are to check safety and find the best dose, with a secondary look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TC-D101 CAR-T cells (a type of immune cell therapy) given after chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If it works, this could point toward a new treatment option for people with a hard-to-treat form of lung cancer that has not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) and small trial with only 24 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Jinling Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••